Biom Therapeutics
PrivateCompany Overview
Biom Therapeutics is a biopharmaceutical company that develops novel therapies for rare neurological diseases, including Angelman syndrome and epilepsy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biom Therapeutics Comparables
Compare Biom Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avata Biosciences | 83% | |
| Argent Biopharma Ltd | 82% | |
| MavriX Bio | 80% | |
Biom Therapeutics Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 526% MoM, from 129 to 808.
- May 2, 2025
Monthly visitors grew 121% MoM, reaching 976.
Biom Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Biom Therapeutics's valuation, stock price, and market status.